产品
编 号：F225077
分子式：C10H8Br2N2O2
分子量：347.99
分子式：C10H8Br2N2O2
分子量：347.99
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
25mg
询价
询价
100mg
询价
询价
结构图
CAS No: 18080-67-6
产品详情
生物活性：
Conoidin A is a cell permeable inhibitor of?T. gondii enzyme peroxiredoxin II (TgPrxII) with nematicidal properties. Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC50 of 23 μM. Conoidin A also inhibits hyperoxidation of mammalian PrxI and PrxII (but not PrxIII). Conoidin A has antioxidant, neuroprotective effects and can be used for the research of ischaemic heart disease.
体内研究：
Conoidin A (intraperitoneal injection; 5?mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HY-N0162) on the ST‐segment elevation.?Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐treatment with conoidin A abolishs the effect of Luteolin. Pre‐treatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDH in vivo.Animal Model:Rat myocardial I/R model
Dosage:5?mg/kg
Administration:Intraperitoneal injection; 5?mg/kg; for three successive days before MI/R injury
Result:Significantly reversed the antioxidative effect of Luteolin.Impaired the protective effects of luteolin.
体外研究：
Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer.Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity?in vitro. Conoidin A also shown to alkylate or crosslink catalytic cysteines of wild type AcePrx-1 in?Ancylostoma ceylanicum?and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII.Conoidin A (5 μM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II.
Conoidin A is a cell permeable inhibitor of?T. gondii enzyme peroxiredoxin II (TgPrxII) with nematicidal properties. Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC50 of 23 μM. Conoidin A also inhibits hyperoxidation of mammalian PrxI and PrxII (but not PrxIII). Conoidin A has antioxidant, neuroprotective effects and can be used for the research of ischaemic heart disease.
体内研究：
Conoidin A (intraperitoneal injection; 5?mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HY-N0162) on the ST‐segment elevation.?Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐treatment with conoidin A abolishs the effect of Luteolin. Pre‐treatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDH in vivo.Animal Model:Rat myocardial I/R model
Dosage:5?mg/kg
Administration:Intraperitoneal injection; 5?mg/kg; for three successive days before MI/R injury
Result:Significantly reversed the antioxidative effect of Luteolin.Impaired the protective effects of luteolin.
体外研究：
Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer.Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity?in vitro. Conoidin A also shown to alkylate or crosslink catalytic cysteines of wild type AcePrx-1 in?Ancylostoma ceylanicum?and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII.Conoidin A (5 μM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备